Blindness is one of the most feared health hazards in our present society; millions of Europeans are threatened by blinding untreatable eye diseases producing costs of several billion Euros. EVI aims at devising and implementing programs and projects for new therapeutic strategies for eye diseases that are difficult or impossible to be treated presently. Its approach will incorporate the most recent scientific developments of the postgenomic area.
The European Vision Institute should be of enormous strategic importance for the future and is targeted towards more immediate policy objectives of improving the competitiveness of European Research assembling the top institutes together with partners from industry and academia. EVI integrates, conducts and supports research that helps to prevent and treat eye diseases and other disorders of vision. This research leads to sight-saving treatments, reduces visual impairment and blindness, and improves the quality of life for people of all ages.
Meeting of the European Vision Institute - Special Interest Focus Group „New Technologies for Outcome Measures in Retina and Glaucoma” in Basel, Switzerland from 08. - 09. November 2018 Read more
How governments decide when to boost basic research funding, and when to scale back support. Read more
The approval last year for the first autonomous artificial intelligence (AI) to make a diagnosis without a physician has opened new doors for the first medical device to use AI to diagnose moderate or worse diabetic retinopathy or macular edema in adults who have diabetes. Read more
Software that uncovers suspicious papers will do little for a community that does not confront organized research fraud. Read more
Many grant funding decisions are random, with luck playing a large part. How can the system be improved, particularly when funds are tight? Read more
The "Gateway to European Vision Research" is a web-based portal service for the European vision research community and major stakeholders.
An award and public recognition by any measure is a sign of inimitability - an acknowledgment that peers and professionals alike agree that a certain person excels in what they do.
Read more about the European Vision Award and the Carl Zeiss Young Investigator Award.
Ophthalmic Research - The Journal for Translational and Clinical Research is official affiliated with the European Vision Institute